Research Publications - Bristol-Myers Squibb



metastatic prostate cancer gleason score 10 life expectancy :: Article Creator

Prostate Cancer Is More Likely In Black Men Than In White Men With The Same PSA Levels

While it's well established that Black men in the United States are more likely to develop prostate cancer and die of it than white men, a new study shows that Black males are also more likely to have prostate cancer at any PSA level.

Prostate-specific antigen (PSA) is a protein made by the prostate (a male sex gland), and levels can be higher in the blood of men who develop prostate cancer. This latest research indicates that Black men may face an increased risk of prostate cancer even at lower PSA levels than white men.

"We know Black men are at higher risk, but our study puts a number to that in terms of PSA value," says Julie Lynch, PhD, RN, an author of the study and the director of the precision medicine research team for VA Informatics and Computing Infrastructure (VINCI), a national resource center for the Department of Veterans Affairs (VA). "What was compelling to me was that a PSA of 4 in Black men is equivalent to a PSA of 13.4 in white men."

A High Cancer Risk at Lower PSA Levels

The scientific paper, published November 6 in Cancer, a journal of the American Cancer Society, also highlighted that Black men with a pre-biopsy PSA of 4.0 ng/mL had a 49 percent risk of prostate cancer detected during their biopsy, compared with a 39 percent risk for white men with the same PSA level.

The American Cancer Society says that PSA levels often go above 4 when prostate cancer develops. Men with a PSA level between 4 and 10 are considered "borderline" and have about a 1 in 4 chance of having cancer.

Drawing on health data from about 75,000 Black and 208,000 white male veterans, Dr. Lynch and her colleagues further noted that prostate cancer was detected in the first prostate biopsy in 55 percent of Black men, compared with 43 percent of white men. The median age for the first biopsy was 63 for Black men and 65 for white men.

RELATED: Understanding Prostate Cancer Survival Rates

After various competing factors were taken into account, Black veterans were found to have a 50 percent greater chance of a prostate cancer diagnosis from their first prostate biopsy than white veterans.

Black men also had 30 percent greater odds of clinically significant aggressive prostate cancer.

"That's important, because you really have to treat aggressive cancer or you will die of it," says Lynch. "You don't want to overtreat, but there's a risk of undertreating, particularly with Black men."

A Call to Address Racial Disparities

An analysis published in 2022 estimated that Black men had about an 80 percent higher risk of prostate cancer and a 220 percent greater risk of death from it than white men.

For Lorelei Mucci, ScD, MPH, a professor of epidemiology with the Harvard T.H. Chan School of Public Health and the director of strategic research partnerships at the American Cancer Society, the research spotlights the urgent need to address the underlying racial disparities in prostate cancer and to better understand why PSA values indicating prostate cancer differ in Black and white men.

"Black men carry an undue burden of prostate cancer," says Dr. Mucci, who was not involved in the research. "The study calls out the importance of a possible lower threshold for biopsy in Black men, while also potentially diagnosing cancers earlier when cure is still possible."

In an effort to address the disparities and negative trends in prostate cancer incidence, Mucci and her collaborators at the American Cancer Society are working on a new initiative called IMPACT, or Improving Mortality Toward Prostate Cancer Together.

It's Lynch's hope that this latest data will empower patients to better evaluate their risk and make more informed decisions about PSA testing in discussion with their primary care provider.

If you're a Black man and your father or grandfather developed prostate cancer early, or died of it, she advises having early discussions with your primary care provider about whether PSA screenings at a younger age and more frequently is a good idea.

"This study illustrates how important it is for clinical guidelines to be informed by research conducted within diverse patient populations," says Lynch. "Thanks to advances in precision medicine, we now understand that cancer screenings should be informed by an individual patient's characteristics — including age, ancestry, family history of cancer, smoking history, other exposures, and perhaps even their genetic risk score for cancer."


Age When Prostate Cancer Appears?

At what age does prostate cancer normally appear?

Sheldon Marks, MD

Most men are diagnosed with prostate cancer late in life, meaning 60, 70s, 80s, now even 90s. There are certain types of cancer in the prostate that can actually start in men in their 40s and 50s, and because of that, that's why we like to be evaluated early and be sure we're not missing those. Those are the ones where we can impact on a man's quality of life and life span with early diagnosis and early intervention.

Narrator

Is prostate cancer a terrible diagnosis these days?

Sheldon Marks, MD

Rarely. Most men will be diagnosed with prostate cancer but they'll live a normal life and die of something else, with the cancer either present and asymptomatic, or not even present at all.

","publisher":"WebMD Video"} ]]>

Hide Video Transcript

Narrator

At what age does prostate cancer normally appear?

Sheldon Marks, MD

Most men are diagnosed with prostate cancer late in life, meaning 60, 70s, 80s, now even 90s. There are certain types of cancer in the prostate that can actually start in men in their 40s and 50s, and because of that, that's why we like to be evaluated early and be sure we're not missing those. Those are the ones where we can impact on a man's quality of life and life span with early diagnosis and early intervention.

Narrator

Is prostate cancer a terrible diagnosis these days?

Sheldon Marks, MD

Rarely. Most men will be diagnosed with prostate cancer but they'll live a normal life and die of something else, with the cancer either present and asymptomatic, or not even present at all. latest videos on Prostate Cancer

Load More


What Is Prostate-Specific Antigen And Why Is It Important For Patients With Prostate Cancer?

Checking PSA levels following treatment is crucial among patients with nonmetastatic, unfavorable risk prostate cancer, according to the co-author of a recent study.

Prostate-specific antigen (PSA) levels can be among the key factors for patients with prostate cancer to be mindful of following treatment, one expert explained to CURE®.

PSA, a protein which is associated with the presence of prostate cancer in the body, is one of factors recently identified by researchers as potentially indicative of which patients with prostate cancer are at high risk for a shorter time until prostate-specific antigen recurrence and failure.

A secondary analysis of a phase 3 clinical trial, results of which were published in JAMA Network Open, found that among patients with nonmetastatic, unfavorable-risk prostate cancer, those who were younger than 70 years old and had a PSA level of 10 ng/mL, as well as a Gleason score (which grades prostate cancer based on a pathologist's review of a biopsy or surgical specimen on a scale of 2 to 10) of 8 or higher had a 43.8% risk of PSA failure at three years.

Study co-author Dr. Mutlay Sayan, an instructor at Harvard Medical School and radiation oncologist at Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, spoke with CURE® about the importance of monitoring PSA levels, which he advised should be tested at least every six months, following completion of treatment.

"What we know is, the shorter the time to recurrence following a treatment in this group of patients, they (more that patients) tend to have not good clinical outcomes," Sayan said.

Visits with a patient's provider will include testing of PSA levels within a few months following treatment, according to the website of the American Cancer Society. While the ACS notes that the frequency of follow-up visits and testing may depend on the stage of a patient's cancer and its chances of recurrence, most doctors will recommend PSA levels be tested approximately every six months for the first five years after treatment, then at least annually after that.

Testing of PSA levels, Sayan noted, are relatively simple from the patient's perspective.

"It's just a quick blood draw in an office," he said. "It's just one needle on your arm and collecting blood. And that's as simple as that is. And it's the best way to monitor (PSA levels) following the definitive treatment.

Transcript:

The best way to monitor after a definite of treatment is to check the PSA level. When the PSA level is reaching a certain point that the patient will be determined to have a biochemical failure, the failure due to PSA rising. That is an indication, perhaps, that the clinical outcome will be worse, and more so in the patient that has a shorter interval time following their definitive treatment. That information itself is important, (because) that can tell us which group of patients that we can do at an early intervention (for). Or (it tells us) before they get their treatment, that we can do a treatment escalation. Those are questions that need to be answered with a (well) designed clinical trial.

This transcript has been edited for length and clarity.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.






Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Mechanism and clinical progression of solid tumors bone marrow metastasis

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions